Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: A prospective cohort study

Li Han Hsu, Pei Chi Hsu, Tien Ling Liao, An Chen Feng, Nei Min Chu, Shu Huei Kao

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Rapidly growing cancer cells secrete growth-promoting polypeptides and have increased proteolytic activity, contributing to tumor progression and metastasis. Their presentation in malignant pleural effusion (MPE) and their predictive value for the outcome of pleurodesis and survival were studied. Methods: Between February 2011 and March 2012, MPE samples were prospectively collected from 61 patients. Twenty-five patients with non-malignant pleural effusion in the same period were included as controls. Pleural fluid osteopontin (OPN), vascular endothelial growth factor (VEGF), and urokinase-type plasminogen activator (uPA) concentrations were measured. Results: Patients with MPE had higher pleural fluid OPN, VEGF, and uPA concentrations than those with non-malignant pleural effusion, but only differences in VEGF were statistically significant (p=0.045). Patients with distant metastases had significantly elevated pleural fluid VEGF concentrations than those without (p=0.004). Pleural fluid OPN, VEGF, and uPA concentrations were positively correlated in most patients. However, there was no significant difference in pleural fluid OPN, VEGF, and uPA concentrations between patients with successful pleurodesis and those without. There was also no significant difference in cancer-specific survival between sub-groups with higher and lower pleural fluid OPN, VEGF, or uPA concentrations. Patients with successful pleurodesis had significantly longer cancer-specific survival than those without (p=0.015). Conclusions: Pleural fluid OPN, VEGF, and uPA concentrations are elevated in MPE but are not satisfactory predictors of pleurodesis outcome or survival. Patients with higher pleural fluid VEGF concentration have higher risk of distant metastasis. Evaluating the benefits of therapy targeting the VEGF pathway in these patients warrants further studies.

Original languageEnglish
Article number463
JournalBMC Cancer
Volume16
Issue number1
DOIs
Publication statusPublished - Jul 13 2016

Fingerprint

Pleurodesis
Malignant Pleural Effusion
Osteopontin
Urokinase-Type Plasminogen Activator
Vascular Endothelial Growth Factor A
Cohort Studies
Prospective Studies
Survival
Pleural Effusion
Neoplasm Metastasis
Neoplasms

Keywords

  • Malignant pleural effusion
  • Osteopontin
  • Pleurodesis
  • Survival
  • Urokinase-type plasminogen activator
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

@article{e81a1c9c627949a280ededb90ff9d315,
title = "Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: A prospective cohort study",
abstract = "Background: Rapidly growing cancer cells secrete growth-promoting polypeptides and have increased proteolytic activity, contributing to tumor progression and metastasis. Their presentation in malignant pleural effusion (MPE) and their predictive value for the outcome of pleurodesis and survival were studied. Methods: Between February 2011 and March 2012, MPE samples were prospectively collected from 61 patients. Twenty-five patients with non-malignant pleural effusion in the same period were included as controls. Pleural fluid osteopontin (OPN), vascular endothelial growth factor (VEGF), and urokinase-type plasminogen activator (uPA) concentrations were measured. Results: Patients with MPE had higher pleural fluid OPN, VEGF, and uPA concentrations than those with non-malignant pleural effusion, but only differences in VEGF were statistically significant (p=0.045). Patients with distant metastases had significantly elevated pleural fluid VEGF concentrations than those without (p=0.004). Pleural fluid OPN, VEGF, and uPA concentrations were positively correlated in most patients. However, there was no significant difference in pleural fluid OPN, VEGF, and uPA concentrations between patients with successful pleurodesis and those without. There was also no significant difference in cancer-specific survival between sub-groups with higher and lower pleural fluid OPN, VEGF, or uPA concentrations. Patients with successful pleurodesis had significantly longer cancer-specific survival than those without (p=0.015). Conclusions: Pleural fluid OPN, VEGF, and uPA concentrations are elevated in MPE but are not satisfactory predictors of pleurodesis outcome or survival. Patients with higher pleural fluid VEGF concentration have higher risk of distant metastasis. Evaluating the benefits of therapy targeting the VEGF pathway in these patients warrants further studies.",
keywords = "Malignant pleural effusion, Osteopontin, Pleurodesis, Survival, Urokinase-type plasminogen activator, Vascular endothelial growth factor",
author = "Hsu, {Li Han} and Hsu, {Pei Chi} and Liao, {Tien Ling} and Feng, {An Chen} and Chu, {Nei Min} and Kao, {Shu Huei}",
year = "2016",
month = "7",
day = "13",
doi = "10.1186/s12885-016-2529-1",
language = "English",
volume = "16",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion

T2 - A prospective cohort study

AU - Hsu, Li Han

AU - Hsu, Pei Chi

AU - Liao, Tien Ling

AU - Feng, An Chen

AU - Chu, Nei Min

AU - Kao, Shu Huei

PY - 2016/7/13

Y1 - 2016/7/13

N2 - Background: Rapidly growing cancer cells secrete growth-promoting polypeptides and have increased proteolytic activity, contributing to tumor progression and metastasis. Their presentation in malignant pleural effusion (MPE) and their predictive value for the outcome of pleurodesis and survival were studied. Methods: Between February 2011 and March 2012, MPE samples were prospectively collected from 61 patients. Twenty-five patients with non-malignant pleural effusion in the same period were included as controls. Pleural fluid osteopontin (OPN), vascular endothelial growth factor (VEGF), and urokinase-type plasminogen activator (uPA) concentrations were measured. Results: Patients with MPE had higher pleural fluid OPN, VEGF, and uPA concentrations than those with non-malignant pleural effusion, but only differences in VEGF were statistically significant (p=0.045). Patients with distant metastases had significantly elevated pleural fluid VEGF concentrations than those without (p=0.004). Pleural fluid OPN, VEGF, and uPA concentrations were positively correlated in most patients. However, there was no significant difference in pleural fluid OPN, VEGF, and uPA concentrations between patients with successful pleurodesis and those without. There was also no significant difference in cancer-specific survival between sub-groups with higher and lower pleural fluid OPN, VEGF, or uPA concentrations. Patients with successful pleurodesis had significantly longer cancer-specific survival than those without (p=0.015). Conclusions: Pleural fluid OPN, VEGF, and uPA concentrations are elevated in MPE but are not satisfactory predictors of pleurodesis outcome or survival. Patients with higher pleural fluid VEGF concentration have higher risk of distant metastasis. Evaluating the benefits of therapy targeting the VEGF pathway in these patients warrants further studies.

AB - Background: Rapidly growing cancer cells secrete growth-promoting polypeptides and have increased proteolytic activity, contributing to tumor progression and metastasis. Their presentation in malignant pleural effusion (MPE) and their predictive value for the outcome of pleurodesis and survival were studied. Methods: Between February 2011 and March 2012, MPE samples were prospectively collected from 61 patients. Twenty-five patients with non-malignant pleural effusion in the same period were included as controls. Pleural fluid osteopontin (OPN), vascular endothelial growth factor (VEGF), and urokinase-type plasminogen activator (uPA) concentrations were measured. Results: Patients with MPE had higher pleural fluid OPN, VEGF, and uPA concentrations than those with non-malignant pleural effusion, but only differences in VEGF were statistically significant (p=0.045). Patients with distant metastases had significantly elevated pleural fluid VEGF concentrations than those without (p=0.004). Pleural fluid OPN, VEGF, and uPA concentrations were positively correlated in most patients. However, there was no significant difference in pleural fluid OPN, VEGF, and uPA concentrations between patients with successful pleurodesis and those without. There was also no significant difference in cancer-specific survival between sub-groups with higher and lower pleural fluid OPN, VEGF, or uPA concentrations. Patients with successful pleurodesis had significantly longer cancer-specific survival than those without (p=0.015). Conclusions: Pleural fluid OPN, VEGF, and uPA concentrations are elevated in MPE but are not satisfactory predictors of pleurodesis outcome or survival. Patients with higher pleural fluid VEGF concentration have higher risk of distant metastasis. Evaluating the benefits of therapy targeting the VEGF pathway in these patients warrants further studies.

KW - Malignant pleural effusion

KW - Osteopontin

KW - Pleurodesis

KW - Survival

KW - Urokinase-type plasminogen activator

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84979656098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979656098&partnerID=8YFLogxK

U2 - 10.1186/s12885-016-2529-1

DO - 10.1186/s12885-016-2529-1

M3 - Article

C2 - 27411914

AN - SCOPUS:84979656098

VL - 16

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 463

ER -